Skip to content
Wednesday, March 29, 2023
Latest:
  • SQI Diagnostics Submits RALI-Dx(TM) IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization
  • Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors
  • Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
  • PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin
  • MindMed Announces Inclusion in FTSE Russell Indexes
Biotech Stock Market News

Biotech Stock Market News

Know First, Act First

  • Cannabis & Cancer
  • General
  • Coronavirus
  • Financing & Fiscal
  • Shareholders

NVAX

General 

This is Why Novavax Has Exploded Higher in Just Weeks

June 29, 2020May 24, 2021 Desiree Justice coronavirus, COVID-19, Novavax Inc., NVAX, U.S. Department of Defense, US FDA

Novavax Inc. has been incredibly explosive since May 2020. Since then, the stock has gapped from a low of $19

Read more

Cannabis

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
BIOTCHNO Cannabis & Cancer 

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

March 31, 2021July 19, 2021 Raza

TOKYO, Mar 31, 2021 – (JCN Newswire) – Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co.,

The Valens Company Expands Cannabis 2.0 & 3.0
BIOTCHNO Cannabis & Cancer 

The Valens Company Expands Cannabis 2.0 & 3.0

February 25, 2021April 20, 2021 Bachittar
PAOG Announces CBD Nutraceuticals Expansion Plan Multimedia Presentation
BIOTCHNO Cannabis & Cancer 

PAOG Announces CBD Nutraceuticals Expansion Plan Multimedia Presentation

February 16, 2021April 30, 2021 Bachittar
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
BIOTCHNO Cannabis & Cancer 

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

February 11, 2021April 30, 2021 Bachittar
  • Disclaimer
  • Privacy Policy
TD Media LLC dba Life Water Media
5826 New Territory Blvd. Unit #2144 Sugar Land, TX 77479